Mesane kanserinde nardilisin-1 düzeyinin araştırılması
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tekirdağ Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Mesane kanseri (MK), mortalite ve morbidite ile ilişkili bir genitoüriner sistem hastalığıdır. MK taramasında sistoskopi sıklığını azaltmak için ideal bir tümör belirteci henüz bulunamamıştır. Son yıllarda nardilisin meme, mide ve özofagus gibi kanser hücrelerinde yüksek oranda eksprese edildiği ve hücre büyümesini desteklediği gösterilmiştir. Bu çalışmada amacımız mesane kanseri tanı ve takibinde serum nardilisin düzeylerinin rolünü araştırmaktır. Çalışma 49 mesane kanserli hasta ve 34 sağlıklı kontrolden oluşturuldu. MK'li hastalarda serum nardilisin-1 düzeyi kontrol grubuna göre anlamlı olarak yüksek saptandı (p=0.000). Aynı zamanda serum nardilisin-1 düzeyleri risk değerlendirmesi ve patolojik evresi yüksek olan hastalarda anlamlı olarak yüksek bulundu (p=0.032 p=0.044 sırasıyla). Çoklu tümör varlığında ve tümör büyüklüğü >3 cm olan hastalarda da anlamlı olarak artış gösterdi (p=0.040 p=0.013 sırasıyla). ROC analizinde eğri altında kalan alan nardilisin-1 için 0,748 (p=0,000) bulundu. MK'de sistematik inflamasyon belirteçleri (CRP, NLO ve SII) anlamlı olarak yüksek bulundu (p=0,000, p=0.000, p=0.000 sırasıyla). Aynı zamanda nardilisin-1 düzeyleri ile CRP ve CAO oranı arasında pozitif korelasyon saptandı (r=0,315 p<0.05 r=0,291 p<0.05). Sonuç olarak serum nardilisin-1 düzeyi mesane kanseri tanısında ve progresyonun izlenmesinde kullanılabilecek potansiyel bir biyobelirteç olabileceğini göstermektedir.
ladder cancer (BC), It is a genitourinary system disease associated with mortality and morbidity. An ideal tumor marker has not yet been found to reduce the frequency of cystoscopy onthe BC screening. In recent years, it has been shown that nardilysin-1 is highly expressed in cancer cells such as breast, stomach and esophagus and tumor proliferation. Our aim in this study is to investigate the role of serum nardilysin-1 levels in the diagnosis and follow-up of BC. The study was composed of 49 patients with BC and 34 healthy controls. Serum nardilysin-1 level was significantly higher in patients with BC than in the control group (p = 0.000). At the same time, serum nardilysin-1 levels were significantly higher in patients with high risk assessment and pathological stage (p = 0.032, p = 0.044, respectively). Moreover, it was significantly increased in the presence of multiple tumors and in patients with tumor size > 3 cm (p = 0.040 p = 0.013 respectively). In ROC analysis, the area under the curve was found 0.748 for nardilysin-1 (p = 0,000). In the BC, systematic inflammation markers (CRP, NLR and SII) were found to be significantly higher in patients with BC(p = 0.000, p = 0.000, p = 0.000, respectively). Also, a positive correlation was found between nardilysin-1 and CRP and CAR ratio (r = 0.315, p <0.05, r = 0,2291, p <0.05). As a result, serum nardilysin-1 level indicates that it may be a potential biomarker that can be used in the diagnosis and monitoring progression response to therapy of bladder cancer.
ladder cancer (BC), It is a genitourinary system disease associated with mortality and morbidity. An ideal tumor marker has not yet been found to reduce the frequency of cystoscopy onthe BC screening. In recent years, it has been shown that nardilysin-1 is highly expressed in cancer cells such as breast, stomach and esophagus and tumor proliferation. Our aim in this study is to investigate the role of serum nardilysin-1 levels in the diagnosis and follow-up of BC. The study was composed of 49 patients with BC and 34 healthy controls. Serum nardilysin-1 level was significantly higher in patients with BC than in the control group (p = 0.000). At the same time, serum nardilysin-1 levels were significantly higher in patients with high risk assessment and pathological stage (p = 0.032, p = 0.044, respectively). Moreover, it was significantly increased in the presence of multiple tumors and in patients with tumor size > 3 cm (p = 0.040 p = 0.013 respectively). In ROC analysis, the area under the curve was found 0.748 for nardilysin-1 (p = 0,000). In the BC, systematic inflammation markers (CRP, NLR and SII) were found to be significantly higher in patients with BC(p = 0.000, p = 0.000, p = 0.000, respectively). Also, a positive correlation was found between nardilysin-1 and CRP and CAR ratio (r = 0.315, p <0.05, r = 0,2291, p <0.05). As a result, serum nardilysin-1 level indicates that it may be a potential biomarker that can be used in the diagnosis and monitoring progression response to therapy of bladder cancer.
Açıklama
Anahtar Kelimeler
Biyokimya, Biochemistry, C reaktif protein, C reactive protein, Kanser hastaları, Cancer patients, Meme hastalıkları, Breast diseases, Meme neoplazmları, Breast neoplasms, Mesane neoplazmları, Urinary bladder neoplasms, Nardilisin, Nardilisin, Neoplazmlar, Neoplasms